Oxylyc use in the comprehensive treatmentof patients with autoimmune thyroiditis
Background. Chronic autoimmune thyroiditis (AIT) is one of the most common autoimmune diseases and the main cause of hypothyroidism. The pathogenesis of AIT is associated with a decrease in the activity of seleno-enzymes, which protect thyroid gland from oxidative stress and, accordingly, an increas...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Publishing House Zaslavsky
2020-08-01
|
| Series: | Mìžnarodnij Endokrinologìčnij Žurnal |
| Subjects: | |
| Online Access: | http://iej.zaslavsky.com.ua/article/view/212742 |
| Summary: | Background. Chronic autoimmune thyroiditis (AIT) is one of the most common autoimmune diseases and the main cause of hypothyroidism. The pathogenesis of AIT is associated with a decrease in the activity of seleno-enzymes, which protect thyroid gland from oxidative stress and, accordingly, an increase in autoimmune processes, which is associated with a deficiency of selenium in endemic areas, including most regions of Ukraine. The purpose of the research was to study the effectiveness of Oxylyc in the comprehensive treatment of autoimmune thyroiditis. Materials and methods. Fifty-six patients aged 26 to 54 years with hypothyroidism on the background of AIT were examined and treated. To assess the effectiveness of treatment, patients were randomized into two groups. Representatives of the first group (26 people) received basic treatment in the form of replacement therapy with levothyroxine in adequate doses. Patients of the second group (30 people) received Oxylyc (one capsule for 3 months on the background of therapy with levothyroxine). Results. A positive effect of Oxylyc on thyroid homeostasis was found, which manifested itself as a significant increase in free triiodothyronine level by 150 % (p < 0.05) and free triiodothyronine/free thyroxine ratio 3,89 times (p < 0.05) without significant intergroup difference. Patients of the main group showed a decrease in thyroid peroxidase antibodies titers by 29.2 % (p < 0.05), while in the comparison group there was no statistically significant change in this indicator. In general, a decrease in thyroid peroxidase antibodies levels by 25 % or more was achieved in 85.2 % of patients. Patients with AIT showed negative correlation between the level of selenium in the serum of venous blood and the titer` of thyroid peroxidase antibodies (r = –0.368, p < 0.05). Conclusions. Oxylyc can be recommended for treatment of AIT with one capsule for 3 months. |
|---|---|
| ISSN: | 2224-0721 2307-1427 |